Who
Josh Riggs
CEO and President
Company insider
Files Form 4 as: CEO and President, Insight Molecular Diagnostics.
In numbers
- Trades disclosed
- 15
- Buys
- 1
- Sells
- 0
- Bought
- $10K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Jan 2023
- Last trade
- 26 Mar 2026
- Last filed
- 30 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code M | —47,170 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code F | $51K12,310 at $4.11 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —47,170 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —47,170 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code M | —47,170 | filing |
| 26 Mar 2026filed 30 Mar 2026 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Code F | $51K12,310 at $4.11 | filing |
| 28 Sep 2025filed 30 Sep 2025 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 26 Mar 2025filed 28 Mar 2025 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —188,679 at $0.00 | filing |
| 20 May 2024filed 22 May 2024 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 11 Apr 2024filed 15 Apr 2024 | IMDX Insight Molecular DiagnosticsDiagnostics & Labs | SEC FORM 4 Bought | $10K3,390 at $2.95 | filing |
| 15 Aug 2023filed 17 Aug 2023 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jun 2023filed 13 Jun 2023 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 9 Jun 2023filed 13 Jun 2023 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 24 Feb 2023filed 28 Feb 2023 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —116,426 at $0.00 | filing |
| 17 Jan 2023filed 19 Jan 2023 | IMDX Insight Molecular Diagnosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —257,485 at $0.00 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) versus Oncocyte (NASDAQ:IMDX) Head to Head ComparisonIMDX · dailypolitical.com · 21 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyIMDX · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Josh Riggs; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.